BAYER AG
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Clinical Trials
2.6k
Trial Phases
5 Phases
Drug Approvals
279
Drug Approvals
Aflibercept Intravitreous Injection
- Product Name
- 艾力雅
- Approval Number
- 国药准字SJ20255004
- Approval Date
- May 19, 2025
Recombinant human interferon beta-1b for injection
- Product Name
- 倍泰龙
- Approval Number
- 国药准字SJ20130094
- Approval Date
- Aug 24, 2023
Iloprost Solution for Inhalation
- Product Name
- 万他维
- Approval Number
- 国药准字HJ20140940
- Approval Date
- Apr 25, 2023
Iloprost Solution for Inhalation
- Product Name
- 万他维
- Approval Number
- 国药准字HJ20140941
- Approval Date
- Apr 25, 2023
Iloprost Solution for Inhalation
- Product Name
- 万他维
- Approval Number
- 国药准字HJ20140939
- Approval Date
- Apr 25, 2023
Aflibercept Intravitreous Injection
- Product Name
- 艾力雅
- Approval Number
- 国药准字SJ20180010
- Approval Date
- Apr 10, 2023
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- Next
Clinical Trials
Distribution across different clinical trial phases (2057 trials with phase data)• Click on a phase to view related trials
A Study to Assess the Safety and Effects of Different Doses of an Investigational Drug, BAY 3389934, in Healthy Japanese Volunteers.
- Conditions
- Sepsis Associated Disseminated Intravascular Coagulation (DIC)
- Interventions
- Drug: Matching Placebo / Diluent
- First Posted Date
- 2025-09-16
- Last Posted Date
- 2025-09-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 16
- Registration Number
- NCT07176728
An Observational Study to Learn More About the Safety of Rivaroxaban in Participants With Peripheral Arterial Disease Who Had Surgery to Improve Blood Flow to Their Legs
- Conditions
- Peripheral Arterial Disease (PAD)
- First Posted Date
- 2025-08-27
- Last Posted Date
- 2025-08-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1500
- Registration Number
- NCT07142655
An Observational Study Called FIRST-2.0 China to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions in a Chinese Population.
- Conditions
- Chronic Kidney DiseaseType 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2025-08-15
- Last Posted Date
- 2025-08-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 5000
- Registration Number
- NCT07124039
- Locations
- 🇨🇳
Inspur Tianjin Regional Electronic Health Records Database, Tianjin, Tianjin, China
A Study to Compare How Much of the Study Treatment Finerenone Gets Into the Blood When the Same Amount is Taken in One and in Two Tablets of Different Strengths in Healthy Male Participants
- Conditions
- Heart Failure With Left Ventricular Ejection Fraction Greater Than or Equal to 40 Per CentHealthy Volunteers
- First Posted Date
- 2025-08-11
- Last Posted Date
- 2025-08-11
- Lead Sponsor
- Bayer
- Target Recruit Count
- 60
- Registration Number
- NCT07116512
- Locations
- 🇩🇪
CRS Clinical Research Services Wuppertal GmbH, Wuppertal, Nordrhein-Westfalen, Germany
A Study Evaluating How Moderate Liver Impairment Affects the Absorption, Distribution, Metabolism, and Elimination of Sevabertinib After a Single Oral Dose
- Conditions
- Hepatic InsufficiencyDrug MetabolismLiver DiseasesPharmacokinetics
- Interventions
- Drug: Sevabertinib
- First Posted Date
- 2025-08-03
- Last Posted Date
- 2025-08-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 20
- Registration Number
- NCT07102095
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, LLC - Oncology Department, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 328
- Next
News
Alnylam Pharmaceuticals Joins Alliance for Genomic Discovery to Accelerate RNAi Drug Development
Alnylam Pharmaceuticals has joined the Alliance for Genomic Discovery as the ninth member, gaining access to a comprehensive clinical genomic database containing 250,000 whole-genomes to accelerate RNA interference therapeutic development.
AskBio Completes Enrollment in Phase 1 Gene Therapy Trial for Rare Neurological Disease MSA-P
AskBio has completed enrollment of 11 participants in its Phase 1 REGENERATE MSA-101 trial testing AB-1005 gene therapy for multiple system atrophy-parkinsonian type (MSA-P), a rare neurodegenerative disease affecting approximately 400,000 people worldwide.
Berlin Center for Gene and Cell Therapies Breaks Ground, Creating European Hub for Advanced Therapeutics
Bayer AG, Charité – Universitätsmedizin Berlin, and the Berlin Institute of Health officially began construction of the Berlin Center for Gene and Cell Therapies in September 2025, marking a significant milestone in European biotechnology infrastructure.
Roivant Sciences Gains Orphan Drug Designation in Japan for Mosliciguat in Pulmonary Hypertension
Roivant Sciences' subsidiary Pulmovant received orphan drug designation from Japan's Ministry of Health, Labour and Welfare for mosliciguat, an inhaled soluble guanylate cyclase activator.
Merck KGaA Appoints David Weinreich as Global Head of R&D to Revitalize Healthcare Pipeline
Merck KGaA has appointed David Weinreich as Global Head of R&D and Chief Medical Officer for its Healthcare business sector, bringing over 20 years of experience and leadership in developing 15 approved drugs worldwide.
High Court Strikes Out Sandoz's £3.9 Million Profit Claim Against Bayer in Rivaroxaban Patent Dispute
The High Court struck out Sandoz's claim for an account of profits against Bayer, reinforcing that cross-undertakings in patent litigation serve compensatory rather than restitutionary purposes.
GIST Treatment Pipeline Shows Robust Activity with 28+ Therapies in Development Across Multiple Clinical Phases
DelveInsight's 2025 pipeline analysis reveals 25+ companies developing 28+ therapies for gastrointestinal stromal tumors, indicating strong industry investment in this rare cancer space.
Major Pharmaceutical Companies Face Surge in Generic Drug Patent Challenges in Early 2025
Major pharmaceutical companies including AstraZeneca, Novartis, and Astellas are defending patents for blockbuster drugs like Lynparza, Entresto, and Xtandi against generic manufacturers in early 2025.
Bayer Partners with Kumquat Biosciences in $1.3 Billion Deal to Develop KRAS G12D Inhibitor for Hard-to-Treat Cancers
Bayer and Kumquat Biosciences announced an exclusive global license and collaboration worth up to $1.3 billion to develop a KRAS G12D inhibitor targeting pancreatic, colorectal, and lung cancers.
German Federal Patent Court Revokes Key Xarelto Patent, Opening Door for Generic Competition
The German Federal Patent Court revoked Bayer's crucial Xarelto patent EP 1 845 961 due to lack of inventive step, contradicting its earlier 2024 opinion that assumed the patent's validity.